Spravato treatment for Deerfield Beach — REMS-certified, insurance-covered TRD care.

RECO Integrated Psychiatry is a certified Spravato treatment site 13 miles north of Deerfield Beach in Delray Beach — 22 minutes up A1A. The office runs esketamine sessions under the required REMS protocol, with in-house psychiatrists managing the concurrent oral antidepressant so treatment is not fragmented across providers. Most Deerfield Beach clients from The Cove, Pioneer Park, and Hillsboro Beach schedule twice-weekly induction sessions in the morning and are cleared for pickup by early afternoon.

Deerfield Beach sits 13 miles south of RECO Integrated Psychiatry’s Delray Beach office, a 22-minute run up A1A when traffic cooperates. For clients navigating treatment-resistant depression, that short distance is meaningful — close enough to keep work, family, and standing appointments intact, far enough that a Spravato session isn’t stacked on top of the routines and stressors driving the illness. This page outlines what Spravato treatment looks like at our office, who it is approved for, and how coverage and scheduling work for Deerfield Beach residents.

Spravato and the REMS protocol — what treatment actually looks like

Esketamine is the S-enantiomer of ketamine, delivered as an intranasal device the client self-administers under nursing supervision. Standard treatment-resistant depression (TRD) dosing starts at 56 mg for the first session and escalates to 84 mg from session two forward, adjusted downward only for tolerability. The device is dosed in two or three sprays per nostril depending on target dose; the client is seated in a reclined position for the duration of administration and monitoring.

Every session runs the same observation block: two hours of post-dose monitoring in a quiet, low-stimulation treatment room. Blood pressure is checked at 40 minutes because transient elevation is expected and clinically meaningful — sessions are not concluded until pressure returns to baseline. Dissociative symptoms are assessed with the Clinician-Administered Dissociative States Scale (CADSS), and sedation is tracked continuously. Clients are not permitted to drive for the remainder of the day; a ride home is a non-negotiable safety requirement.

RECO Integrated Psychiatry is enrolled in the Spravato REMS program, and all registration paperwork, per-session monitoring documentation, and outcome reporting are handled by the office. There is nothing the client files with the manufacturer or the specialty pharmacy directly.

The induction and maintenance schedule

The FDA-labeled TRD protocol runs twice weekly for four weeks — eight induction sessions — followed by weekly dosing for four weeks, then every one to two weeks for maintenance based on symptom trajectory. Clients tracked with the PHQ-9 across induction often see meaningful movement within the first week, but sustained response typically consolidates over the full induction block rather than early. Response is defined as a 50% reduction in PHQ-9 score; remission as a total score under five.

The separate indication for major depressive disorder with acute suicidal ideation or behavior runs twice weekly for four weeks as an add-on to comprehensive standard-of-care management. Maintenance beyond that acute phase is a separate clinical decision and often transitions to the TRD schedule if depressive symptoms persist. Discontinuation, when appropriate, is done on a taper — either by spacing sessions further apart or by re-anchoring to an alternative maintenance strategy — not by abrupt stop.

Missed sessions during induction are common with real work and family schedules; the office reschedules within the same week when possible to preserve the twice-weekly cadence, which is what the pivotal trial data supports.

Spravato with an oral antidepressant, not instead of one

The FDA approval for Spravato is specifically for esketamine in conjunction with a newly initiated oral antidepressant. This is not a technicality — the pivotal TRANSFORM-2 and SUSTAIN-1 trials paired esketamine with an SSRI or SNRI, and the labeled indication reflects that pairing. Monotherapy Spravato is not the approved use and is not what our office offers.

For clients arriving on a partial-response SSRI or SNRI — sertraline, escitalopram, venlafaxine, duloxetine — that oral agent typically continues through Spravato induction. For clients who have failed multiple antidepressants and arrive on nothing, an oral agent is initiated concurrently with the first Spravato session. Adjunctive medications already in the regimen (aripiprazole, quetiapine, lithium, bupropion) are reassessed by the psychiatrist rather than automatically continued or stopped.

Concurrent medication management is done in-house by RECO’s psychiatry team — the same clinician oversees both the Spravato treatment plan and the oral regimen. That avoids the common problem of a Spravato-only site handing coverage of the SSRI back to an outside prescriber who is not seeing the client weekly during induction.

Spravato versus IV ketamine and how we choose

Spravato and IV ketamine are related but not interchangeable. Spravato is FDA-approved for TRD and MDD with suicidality, is covered by most commercial insurance for documented TRD, and uses fixed nasal dosing (56 mg or 84 mg). IV ketamine is off-label for depression, is typically cash-pay in the $400-$600 per infusion range, and allows weight-based and response-based titration that some cases require for adequate effect.

Session logistics are similar on the surface — both require observed dosing, both require roughly two hours end-to-end, both require a driver. The differences that matter clinically are prior treatment response, insurance coverage, and how much titration flexibility the case demands. A client who responded well to IV ketamine historically but wants insurance-covered maintenance is usually a Spravato candidate; a client who has not tolerated fixed dosing or needs weight-adjusted higher exposure is often better served by IV.

The consult walks through both options. The psychiatrist reviews prior trials, current medication list, insurance benefits, and schedule constraints before recommending one over the other — the choice is not made before the client is in the room.

What to expect on your first visit

The first appointment is a psychiatric evaluation, not a Spravato session. The psychiatrist reviews prior antidepressant trials (agent, dose, duration, response, side effects — the standard failed-trial documentation TRD is defined by), current medications, medical history relevant to blood pressure and cardiovascular risk, and completes a PHQ-9 and GAD-7 at baseline. Treatment-resistant depression is confirmed by inadequate response to at least two antidepressants of adequate dose and duration in the current episode.

If the client is a candidate, the office runs benefits verification and prior authorization with the carrier before the first dosing session is scheduled — this typically takes three to seven business days depending on the plan. The first dosing session is usually scheduled within one to two weeks of the consult. Clients receive written pre-visit instructions: no food two hours prior, no alcohol or benzodiazepines the day of, driver arranged, and clothing appropriate for two hours of low-stimulation monitoring.

Insurance and admissions from Deerfield Beach

RECO Integrated Psychiatry accepts most major commercial plans including Florida Blue, Aetna, Cigna, UnitedHealthcare, Humana, and BCBS. Spravato coverage under these plans for documented TRD is standard; prior authorization is required and handled by the office. Coverage for the MDD-with-suicidality indication is more variable and reviewed case by case at intake.

For Deerfield Beach clients, the drive to the Delray Beach office is 13 miles — roughly 22 minutes via A1A or I-95 depending on time of day. Clients from The Cove, Pioneer Park, Hillsboro Beach, Cresthaven, and Goldcoast Centre are all within a similar window. Morning induction sessions are popular because the two-hour monitoring block plus the no-driving requirement typically clears in time for an early afternoon pickup, so the treatment day does not consume a full workday for the driver either.

Serving residents of: The Cove, Pioneer Park, Hillsboro Beach, Cresthaven, Goldcoast Centre.